Bioengineering Strategies for the Improvement of Therapies in Spinal Diseases

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Biomedical Engineering and Biomaterials".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 753

Special Issue Editor

Department of Neurosurgery, Gil Medical Center, Gachon University College of Medicine, Incheon 21565, Republic of Korea
Interests: spine; minimally invasive surgery; biomaterial; advanced technology

Special Issue Information

Dear Colleagues,

The field of spinal disease treatment has witnessed gradual development alongside recent advancements in bioengineering and technology. The constant updates in drugs, biomaterials, diagnostic techniques, surgical procedures, and bioinformatics offer a range of advanced methods for treating spinal diseases. However, limited communication between researchers and clinicians has hindered the progress of these cutting-edge biological and technological advancements.

This Special Issue of Bioengineering aims to provide a platform for interdisciplinary exchange and foster the expansion of innovative bioengineering strategies for spinal disease treatment. By facilitating updates and collaboration, we aim to establish a foundation for the future development of diverse diagnostic and therapeutic tools for spinal diseases.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

Biomedical devices and technology for the spine:

Design and development of surgical devices and their application.

Biosensors, biochips, and diagnostic tools for spinal disease. 

Updated surgical procedures or technologies: robotic surgery, cutting-edge MIS, deformity surgery, etc.

Prosthetics, assistive devices, and rehabilitation technologies for spinal conditions.

Biomaterials and tissue engineering for the spine:

Advanced drug investigation and treatment for spinal diseases like osteoporosis or spinal stenosis.

Novel biomaterials and their applications in surgical procedures, such as spinal fusion or anti-cancer drugs.

Cell-material interactions and tissue engineering approaches for conditions like disc regeneration or spinal cord injury.

Bioinformatics and biomechanics of the spine systems:

Data analysis based on advanced methods like big data analytics, machine learning, or artificial intelligence.

Biomechanical analysis or computational modeling of spine systems. 

Digital therapeutics for managing pain related to spinal conditions.

Please note that this list is not exhaustive, and contributions related to other relevant aspects of bioengineering for spinal disease treatment are also welcome in this Special Issue.

We look forward to receiving your contributions.

Dr. Seong Son
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • spinal disease
  • advanced treatment
  • biomedical devices
  • surgical technology
  • biomaterials
  • tissue engineering
  • bioinformatics
  • biomechanics
  • digital therapeutics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


12 pages, 2086 KiB  
Outcome of Percutaneous Endoscopic Lumbar Discectomy in Relation to the Surgeon’s Experience: Propensity Score Matching
by Seong Son, Michael Y. Oh, Han Byeol Park and Alexander M. Lopez
Bioengineering 2024, 11(4), 312; - 26 Mar 2024
Viewed by 548
Percutaneous endoscopic lumbar discectomy (PELD) presents a challenging learning curve, and the correlation between surgeon experience and clinical outcomes remains contentious. This retrospective study aimed to compare the outcomes of PELD performed by a single surgeon at beginner and experienced stages. Propensity score [...] Read more.
Percutaneous endoscopic lumbar discectomy (PELD) presents a challenging learning curve, and the correlation between surgeon experience and clinical outcomes remains contentious. This retrospective study aimed to compare the outcomes of PELD performed by a single surgeon at beginner and experienced stages. Propensity score matching selected 150 patients (75 per group) with a minimum 3-year follow-up. Clinical and radiological outcomes, perioperative complications, and adverse events were assessed. Baseline characteristics, pain improvement, patient satisfaction, and radiological outcomes did not differ between the groups. However, operation time was longer in the beginner group than in the experienced group (57.5 min [IQR, 50.0–70.0] versus 50.0 min [IQR, 45.0–55.0], p < 0.001). The beginner group had higher perioperative complication rates (eight patients [10.7%] versus one patient [1.3%], with a hazard ratio of 8.836 [95% CI, 1.077–72.514], p = 0.034) and lower 3-year survival without adverse events (19 patients [25.3%] in the beginner group and 10 patients [13.3%] in the experienced group, p = 0.045). Our findings indicate that the clinical outcomes were more favorable in patients operated on at the experienced stage compared to those treated at the beginner stage. Full article
Show Figures

Figure 1

Back to TopTop